Neuroscience
Our team understands the crucial role of rigorous neurological assessments, biomarkers, neuroimaging techniques, and the use of appropriate clinical endpoints in neuroscience trials.
We offer extensive experience across a range of neurological conditions, ensuring comprehensive patient care and data collection throughout complex neurological trials.
We offer extensive experience across a range of neurological conditions, including:
- Dementia, Alzheimer’s and Parkinson’s Disease
- Epileptiform disorders
- Other neurodegenerative diseases
- Movement disorders
- Rare genetic neurological conditions
Disciplined,
Cost-Efficient Execution
while maintaining the Highest Quality
Local Trials,
Global Approvals
Access FDA Regulatory Expertise
Our Clinical Team has over
120
years
of Combined Clinical Trial Experience
Neuroscience Clinical Trial Resources
Alzheimer’s Disease
From Diagnosis to Clinical Trial Optimization. Addressing key challenges, pivotal endpoints, and strategies to enhance trial success.
Migraine
Understanding the Enigma of a Prevalent Neurological Disorder.
Phelan-McDermid Syndrome
Navigating Diagnostic Criteria, Trial Endpoints, and Drug Development Challenges.
Multiple Sclerosis
Understanding MS: Epidemiology, Clinical Implications, and Strategies for Clinical Trial Success.
Parkinson’s Disease
Explore Diagnostic Criteria, Clinical Trial Challenges, and Therapeutic Innovations.
ALS
Dive into Amyotrophic Lateral Sclerosis Diagnosis Criteria, Drug Development, and Clinical Trial Challenges.
Addressing Common Pain Points Associated with Neuroscience Clinical Trials
Patient Recruitment and Retention
Problem:
Neurological disorders can be rare and recruiting enough eligible participants for a study can be challenging. Moreover, due to the chronic or progressive nature of many conditions, retaining participants for the duration of the trial can be tough.
iNGENū CRO addresses this pain point with Enhanced Recruitment Strategies:
iNGENū leverages a global network of research sites and patient advocacy groups, utilising advanced data analytics to target and recruit suitable participants efficiently. Through continuous patient engagement and education, we ensure high retention rates throughout our trials.
Complexity of Endpoints
Problem:
Neurological outcomes can be subjective and may require specialized scales or biomarkers. Ensuring consistency and reliability in endpoint measurements across different investigators and sites can be challenging.
iNGENū CRO addresses this pain point with Standardization and Training:
We implement standardised protocols for all endpoint assessments and provide intensive training for investigators and site personnel. By employing advanced digital tools, we ensure data consistency and reduce variability across sites.
Safety Monitoring
Problem:
Some neurological interventions, especially those that are invasive or novel, may carry significant risks. Monitoring for adverse events and ensuring participant safety is paramount.
iNGENū CRO addresses this pain point with Rigorous Safety Protocols:
We have established robust safety monitoring systems, with real-time data tracking and quick response mechanisms, ensuring the well-being of participants is prioritized at every stage.
Heterogeneity of Diseases
Problem:
Neurological disorders can manifest in various ways in different patients, making it difficult to group patients and interpret results.
iNGENū CRO addresses this pain point with Personalised Approach:
Recognizing the diverse nature of neurological diseases, we employ stratification techniques and personalised medicine approaches. This helps in grouping patients more effectively and interpreting data in a more nuanced manner.
Long Study Duration
Problem:
Many neurological disorders progress slowly, requiring long study durations to observe therapeutic effects or disease progression, which can be resource-intensive.
iNGENū CRO addresses this pain point with Innovative Trial Designs:
To counteract the long durations often required in neurological trials, we adopt adaptive trial designs, interim analyses, and predictive modeling. This not only accelerates the trial process but also optimizes the use of resources.
The iNGENū CRO Difference
Local Trials, Global Approvals
We uniquely combine Australian expertise with direct FDA submission capabilities.
Disciplined, Cost-Efficient Execution
iNGENū CRO takes a highly strategic approach to clinical research.
Australian-Headquartered, Asia-Pacific Reach
We provide sponsors with comprehensive trial capabilities.
We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug. We have been very happy with all aspects of the management of the clinical trial.
Ready to discuss your Neuroscience Clinical Trial?